TABLE 7.
Comparison between first and second cohorts
| First-surge cohort (n = 32) | Second-surge cohort (n = 47) | P | |
|---|---|---|---|
| Age, y, median (IQR) | 65 (51–69) | 65 (57–72) | 0.52 |
| Sex, n (%) | |||
| Female | 16 (50) | 24 (51) | 0.93 |
| Ethnicity, n (%) | 0.45 | ||
| Caucasian | 16 (50) | 32 (68) | |
| Hispanic | 9 (28) | 8 (17) | |
| African American | 7 (22) | 4 (8) | |
| Asian | 0 (0) | 3 (6) | |
| Transplant indication, n (%) | 0.11 | ||
| ILD | 15 (47) | 28 (59) | |
| Transplant type, n (%) | 0.85 | ||
| Single | 17 (53) | 26 (55) | |
| Years since transplant, median (IQR) | 5.6 (2–8.6) | 4.3 (2–9.7) | 0.77 |
| BOS stage, n (%) | 0.40 | ||
| 1 | 4 (13) | 5 (11) | |
| 2 | 2 (6) | 5 (11) | |
| 3 | 1 (3) | 4 (9) | |
| Baseline IS regimen, n (%) | |||
| Mycophenolate ≥2000 mg/d | 13 (41) | 16 (34) | 0.10 |
| Azathioprine ≥150 mg/d | 2 (6) | 1 (2) | |
| No cell-cycle inhibitor | 1 (3) | 9 (19) | |
| Tacrolimus | 24 (75) | 46 (98) | 0.004 |
| Prednisone ≥10 mg/d | 7 (22) | 20 (43) | 0.06 |
| Azithromycin for BOS | 17 (53) | 21 (45) | 0.47 |
| Recent IS augmentation, n (%) | 8 (25)a | 16 (34)b | 0.40 |
| Comorbidities, n (%) | |||
| Hypertension | 18 (56) | 35 (74) | 0.09 |
| CKD | 21 (65) | 29 (62) | 0.82 |
| Heart disease | 6 (19) | 12 (26) | 0.49 |
| Diabetes | 14 (44) | 26 (55) | 0.32 |
| Obesity (BMI ≥30) | 8 (25) | 2 (4) | 0.018 |
| Active malignancy | 1 (3) | 6 (13) | 0.14 |
| Duration of symptoms (d) before testing, median (IQR) | 4 (1.75–7.25) | 3 (1.75–6) | 0.11 |
| Disease severity, n (%) | |||
| Mild disease | 5 (16) | 16 (34) | 0.070 |
| Moderate disease | 14 (44) | 18 (38) | 0.633 |
| Severe disease | 13 (41) | 13 (28) | 0.234 |
| Hospitalization, n (%) | 27 (84) | 31 (66) | 0.074 |
| Mechanical ventilation, n (%) | 10 (31%) | 7 (15) | 0.084 |
| Mortality, n (%) | 11 (34) | 8 (17) | 0.078 |
aThree percent received induction therapy (basiliximab + solumedrol), 3% received steroid pulse, 25% received steroid taper, and 8% received rATG.
bEight percent received induction therapy (basiliximab + solumedrol), 11% received steroid pulse, 6% received steroid taper, and 8% received rATG.
BMI, body mass index; BOS, bronchiolitis obliterans syndrome; CKD, chronic kidney disease; ILD, interstitial lung disease; IQR, interquartile range; IS, immunosuppression.